Figure 3.
Figure 3. KDM6B overexpression combined with chronic low-dose LPS stimulation led to changes in BM hematopoietic stem and progenitor cells of mice. Results are based on adult Vav-KDM6B mice and wild-type (WT) controls treated with low-dose LPS (6 µg/mouse) or PBS every other day for 6 weeks (LPS: N = 12 Vav-KDM6B, N = 13 WT; PBS: N = 16 Vav-KDM6B, N = 16 WT, unless otherwise noted). All error bars are based on ± SEM. (A-B) Percentage of BM long-term hematopoietic stem cells (LT-HSCs) and common myeloid progenitors (CMP) in indicated mice. (C) G2 colony-forming units in serial methylcellulose colony formation assays using LSK BM cells isolated from donor mice (LPS: N = 13 Vav-KDM6B, N = 13 WT; PBS: N = 17 Vav-KDM6B, N = 17 WT). (D) Kinetics of peripheral blood myeloid (Gr1-positive) cell chimerism based on CD45.2 percentage in recipient mice (LPS: N = 8 Vav-KDM6B, N = 9 WT; PBS: N = 11 Vav-KDM6B, N = 12 WT). (E) Representative flow cytometry plots for CD45.2 cells from the peripheral blood of recipient mice 3 months after competitive transplantation by donor BM cells. (F-G) Cell chimerism in BM total cell and LT-HSC populations based on CD45.2 percentage in recipient mice 6 months after competitive transplantation (LPS: N = 8 Vav-KDM6B, N = 9 WT; PBS: N = 11 Vav-KDM6B, N = 12 WT)

KDM6B overexpression combined with chronic low-dose LPS stimulation led to changes in BM hematopoietic stem and progenitor cells of mice. Results are based on adult Vav-KDM6B mice and wild-type (WT) controls treated with low-dose LPS (6 µg/mouse) or PBS every other day for 6 weeks (LPS: N = 12 Vav-KDM6B, N = 13 WT; PBS: N = 16 Vav-KDM6B, N = 16 WT, unless otherwise noted). All error bars are based on ± SEM. (A-B) Percentage of BM long-term hematopoietic stem cells (LT-HSCs) and common myeloid progenitors (CMP) in indicated mice. (C) G2 colony-forming units in serial methylcellulose colony formation assays using LSK BM cells isolated from donor mice (LPS: N = 13 Vav-KDM6B, N = 13 WT; PBS: N = 17 Vav-KDM6B, N = 17 WT). (D) Kinetics of peripheral blood myeloid (Gr1-positive) cell chimerism based on CD45.2 percentage in recipient mice (LPS: N = 8 Vav-KDM6B, N = 9 WT; PBS: N = 11 Vav-KDM6B, N = 12 WT). (E) Representative flow cytometry plots for CD45.2 cells from the peripheral blood of recipient mice 3 months after competitive transplantation by donor BM cells. (F-G) Cell chimerism in BM total cell and LT-HSC populations based on CD45.2 percentage in recipient mice 6 months after competitive transplantation (LPS: N = 8 Vav-KDM6B, N = 9 WT; PBS: N = 11 Vav-KDM6B, N = 12 WT)

Close Modal

or Create an Account

Close Modal
Close Modal